Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
5.77
USD
+16.80%
+22.25%
-12.84%
Presentation Operator MessageOperator (Operator)Good day, and thank you for standing by, and w...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating
May. 10
MT
Earnings Flash (TELA) TELA BIO Posts Q1 Revenue $16.6M, vs. Street Est of $16.3M
May. 09
MT
Transcript : TELA Bio, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
TELA Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 09
CI
TELA Bio, Inc. Provides Revenue Guidance for the Year 2024
May. 09
CI
TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR
Apr. 15
CI
Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating
Mar. 22
MT
Transcript : TELA Bio, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21
Earnings Flash (TELA) TELA BIO Reports Q4 Revenue $17M, vs. Street Est of $16.4M
Mar. 21
MT
TELA Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Mar. 21
CI
TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2024
Mar. 21
CI
TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX
Mar. 21
CI
MiMedx Group to Buy Distribution Rights for TELA Bio's Wound Care Product
Mar. 20
MT
MiMedx Group, Inc. Enters into an Agreement with Tela Bio, Inc. to Obtain Exclusive Rights to Its Manufacturing and Supply Agreement
Mar. 20
CI
Transcript : TELA Bio, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
Earnings Flash (TELA) TELA BIO Posts Q3 Revenue $15.1M, vs. Street Est of $16.2M
Nov. 09
MT
TELA Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc
23-09-28
CI
Advanced Medical to commercialise LiquiBandFix8 in US under Tela deal
23-09-18
AN
Advanced Medical Solutions Partners with Tela Bio for US Commercialization of Surgical Device
23-09-18
MT
Advanced Medical Solutions Group plc Signs Agreement with TELA Bio, Inc
23-09-18
CI
TELA Bio, Inc.(NasdaqGM:TELA) added to S&P Global BMI Index
23-09-18
CI
TELA Bio Launches OviTex Product to Support Implants in Plastic, Reconstructive Surgery
23-08-16
MT
TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery
23-08-16
CI
Transcript : TELA Bio, Inc., Q2 2023 Earnings Call, Aug 09, 2023
23-08-09
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
More about the company
Last Close Price
5.77
USD
Average target price
14.2
USD
Spread / Average Target
+146.10%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1